QuidelOrtho Q2 revenue rises 3% to $631 million; full-year guidance cut
QuidelOrtho reported second-quarter 2026 total revenue of $631 million, up 3% as reported, and a GAAP net loss of $93 million, narrower than the $255 million loss a year earlier. The company cut its full-year 2026 revenue, adjusted EBITDA and adjusted EPS guidance and withdrew its free cash flow guidance, citing China demand headwinds and a softer global respiratory environment.
Key points
- Q2 2026 total revenue $631 million, up 3% as reported and 2% in constant currency; excluding China, up 6%
- GAAP net loss $93 million, or $1.36 per share, versus $255 million prior-year; adjusted diluted EPS $0.13
- Full-year 2026 revenue guidance lowered to $2.52 billion to $2.60 billion from $2.70 billion to $2.75 billion
- Adjusted EBITDA guidance lowered to $540 million to $560 million from $615 million to $630 million; free cash flow guidance withdrawn (previously $100 million to $120 million)
The filing
Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.